Liquid Biopsy Tech Made Strides in 2023 for Residual Cancer Detection, Monitoring

In years past, Medicare had agreed to reimburse minimal residual disease (MRD) testing in colorectal cancer, which was the first clinical niche that most MRD innovators explored. But two leading companies, Natera and NeoGenomics, made an important next step in 2023, winning local coverage determinations through the MolDx program for a newer indication, early-stage breast cancer.

Source: https://www.genomeweb.com/molecular-diagnostics/liquid-biopsy-tech-made-strides-2023-residual-cancer-detection-monitoring